Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary.
作者信息
Fontana Marianna, Gillmore Julian D, Witteles Ronald M, Laryea Ben, Dworkin Marc, Payne Ann, Kochman Fran, Eraly Satish, Maurer Mathew S
机构信息
aNational Amyloidosis Centre, Division of Medicine, University College London, Royal Free Hospital, London, UK.
bDivision of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA, USA.
出版信息
Future Cardiol. 2025 Jun;21(8):555-565. doi: 10.1080/14796678.2025.2493019. Epub 2025 May 15.
Abstract
摘要
相似文献
1
Treatment with vutrisiran in people with transthyretin amyloidosis with cardiomyopathy: a plain language summary.
Future Cardiol. 2025 Jun;21(8):555-565. doi: 10.1080/14796678.2025.2493019. Epub 2025 May 15.
2
Outpatient Worsening Heart Failure in Patients With Transthyretin Amyloidosis With Cardiomyopathy in the HELIOS-B Trial.
J Am Coll Cardiol. 2025 Feb 25;85(7):753-761. doi: 10.1016/j.jacc.2024.11.015. Epub 2024 Nov 18.
3
Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B.
J Am Coll Cardiol. 2025 Apr 30. doi: 10.1016/j.jacc.2025.04.008.
4
Impact of Heart Failure Severity on Vutrisiran Efficacy in Transthyretin Amyloidosis With Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1927-1939. doi: 10.1016/j.jacc.2025.03.477. Epub 2025 Mar 17.
5
Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy.
J Am Coll Cardiol. 2025 May 27;85(20):1943-1955. doi: 10.1016/j.jacc.2025.03.454. Epub 2025 Mar 17.
6
Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy.
N Engl J Med. 2025 Jan 2;392(1):33-44. doi: 10.1056/NEJMoa2409134. Epub 2024 Aug 30.
7
How did transthyretin amyloid cardiomyopathy progress in patients who took placebo in the study ATTR-ACT? A plain language summary.
Future Cardiol. 2022 Mar 17. doi: 10.2217/fca-2021-0150.
8
Tafamidis and quality of life in people with transthyretin amyloid cardiomyopathy in the study ATTR-ACT: A plain language summary.
Future Cardiol. 2022 Mar;18(3):165-172. doi: 10.2217/fca-2021-0095. Epub 2021 Nov 15.
9
Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy.
Neurol Ther. 2023 Oct;12(5):1759-1775. doi: 10.1007/s40120-023-00522-4. Epub 2023 Jul 31.
10
Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy.
Eur J Heart Fail. 2024 Feb;26(2):397-410. doi: 10.1002/ejhf.3138. Epub 2024 Feb 6.
Zotero 插件